CoChat
Sign Up
Cited by 64

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies

Li, Qi, He, Guangpeng, Yu, Yifan, Li, Xinyu, Peng, Xueqiang, Yang, Liang·2024·Stem Cell Research & Therapy
DOI 10.1186/s13287-024-04061-zPMC PMC11583673
Open this paper in CoChat — free account

Abstract

Cancer stem cells (CSCs) represent a small yet pivotal subset of tumor cells endowed with self-renewal capabilities. These cells are intricately linked to tumor progression and are central to drug resistance, metastasis, and recurrence. The tumor microenvironment (TME) encompasses the cancer cells and their surrounding milieu, including immune and inflammatory cells, cancer-associated fibroblasts, adjacent stromal tissues, tumor vasculature, and a variety of cytokines and chemokines. Within the TME, cells such as immune and inflammatory cells, endothelial cells, adipocytes, and fibroblasts release growth factors, cytokines, chemokines, and exosomes, which can either sustain or disrupt CSCs, thereby influencing tumor progression. Conversely, CSCs can also secrete cytokines, chemokines, and exosomes, affecting various components of the TME. Exosomes, a subset of extracellular vesicles (EVs), carry a complex cargo of nucleic acids, proteins, and lipids, playing a crucial role in the communication between CSCs and the TME. This review primarily focuses on the impact of exosomes secreted by CSCs (CSC-exo) on tumor progression, including their roles in maintaining stemness, promoting angiogenesis, facilitating metastasis, inducing immune suppression, and contributing to drug resistance. Additionally, we discuss how exosomes secreted by different cells within the TME affect CSCs. Finally, we explore the potential of utilizing exosomes to mitigate the detrimental effects of CSCs or to target and eliminate them. A thorough understanding of the exosome-mediated crosstalk between CSCs and the TME could provide valuable insights for developing targeted therapies against CSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-024-04061-z

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Exosomes biogenesis and release. Exosome formation and release encompass several steps, starting with endocytosis, followed by the formation of multivesicular bodies (MVBs), and culminating in the release of exosomes into the extracellular space via fusion with the plasma membrane
Fig. 1 Exosomes biogenesis and release. Exosome formation and release encompass several steps, starting with endocytosis, followed by the formation of multivesicular bodies (MVBs), and culminating in the release of exosomes into the extracellular space via fusion with the plasma membraneCC BY · PubMed Central
Fig. 2 Cancer stem cell-derived exosomes are released into the cells within the tumor microenvironment, where they play a role in influencing tumor progression
Fig. 2 Cancer stem cell-derived exosomes are released into the cells within the tumor microenvironment, where they play a role in influencing tumor progressionCC BY · PubMed Central
Fig. 3 Other cells in the tumor microenvironment also secrete exosomes that impact cancer stem cells
Fig. 3 Other cells in the tumor microenvironment also secrete exosomes that impact cancer stem cellsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 121

  1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. · DOI
  2. Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721–43. · DOI · Paper page
  3. Prasetyanti PR, Medema JP. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16(1):41. · DOI
  4. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8. · DOI · Paper page
  5. Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 2024;43(1):197–228. · DOI
  6. Saw PE, Liu Q, Wong PP, Song E. Cancer stem cell mimicry for immune evasion and therapeutic resistance. Cell Stem Cell. 2024;31(8):1101–12. · DOI
  7. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27. · DOI · Paper page
  8. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8. · DOI · Paper page
  9. Peng C, Xu Y, Wu J, Wu D, Zhou L, Xia X. TME-Related biomimetic strategies against Cancer. Int J Nanomed. 2024;19:109–35. · DOI
  10. Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the Tumor Microenvironment. Cancer Discov. 2021;11(4):933–59. · DOI
  11. Cocozza F, Grisard E, Martin-Jaular L, Mathieu M, Théry C, SnapShot. Extracell Vesicles Cell. 2020;182(1):262–e1.
  12. He G, Peng X, Wei S, Yang S, Li X, Huang M, et al. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Mol Cancer. 2022;21(1):19. · DOI
  13. Sun Z, Wang L, Zhou Y, Dong L, Ma W, Lv L, et al. Glioblastoma stem cell-derived Exosomes Enhance Stemness and Tumorigenicity of Glioma cells by transferring Notch1 protein. Cell Mol Neurobiol. 2020;40(5):767–84. · DOI
  14. Huang H, Hou J, Liu K, Liu Q, Shen L, Liu B, et al. RAB27A-dependent release of exosomes by liver cancer stem cells induces nanog expression in their differentiated progenies and confers regorafenib resistance. J Gastroenterol Hepatol. 2021;36(12):3429–37. · DOI
  15. Li W, Zhang L, Guo B, Deng J, Wu S, Li F, et al. Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma. Mol Cancer. 2019;18(1):22. · DOI
  16. Hwang WL, Yang MH. Numb is involved in the non-random segregation of subcellular vesicles in colorectal cancer stem cells. Cell Cycle. 2016;15(20):2697–703. · DOI
  17. Dai W, Jin X, Han L, Huang H, Ji Z, Xu X, et al. Exosomal lncRNA DOCK9-AS2 derived from cancer stem cell-like cells activated Wnt/β-catenin pathway to aggravate stemness, proliferation, migration, and invasion in papillary thyroid carcinoma. Cell Death Dis. 2020;11(9):743. · DOI · Paper page
  18. Han T, Chen L, Li K, Hu Q, Zhang Y, You X, et al. Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer? Mol Cancer. 2023;22(1):197. · DOI
  19. Geindreau M, Bruchard M, Vegran F. Role of cytokines and chemokines in Angiogenesis in a Tumor Context. Cancers (Basel). 2022;14(10). · DOI
  20. Collet G, El Hafny-Rahbi B, Nadim M, Tejchman A, Klimkiewicz K, Kieda C. Hypoxia-shaped vascular niche for cancer stem cells. Contemp Oncol (Pozn). 2015;19(1a):A39–43.
  21. Wang ZF, Liao F, Wu H, Dai J. Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma. J Exp Clin Cancer Res. 2019;38(1):201. · DOI
  22. Sun X, Ma X, Wang J, Zhao Y, Wang Y, Bihl JC, et al. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal. Oncotarget. 2017;8(22):36137–48. · DOI
  23. Treps L, Perret R, Edmond S, Ricard D, Gavard J. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles. 2017;6(1):1359479. · DOI
  24. Lindoso RS, Collino F, Camussi G. Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells. Oncotarget. 2015;6(10):7959–69. · DOI
  25. Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24–31. · DOI
  26. Kumari A, Kashyap D, Garg VK. Osteopontin in cancer. Adv Clin Chem. 2024;118:87–110. · DOI
  27. Khalil A, Medfai H, Poelvoorde P, Kazan MF, Delporte C, Van Antwerpen P, et al. Myeloperoxidase promotes tube formation, triggers ERK1/2 and akt pathways and is expressed endogenously in endothelial cells. Arch Biochem Biophys. 2018;654:55–69. · DOI
  28. Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A. Cancer stem cells: the root of tumor recurrence and metastases. Semin Cancer Biol. 2017;44:10–24. · DOI
  29. Zhang J, Hu Z, Horta CA, Yang J. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Semin Cancer Biol. 2023;88:46–66. · DOI
  30. Fontana R, Mestre-Farrera A, Yang J. Update on epithelial-mesenchymal plasticity in Cancer Progression. Annu Rev Pathol. 2024;19:133–56. · DOI
  31. Khan AQ, Hasan A, Mir SS, Rashid K, Uddin S, Steinhoff M. Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy. Semin Cancer Biol. 2024;100:1–16. · DOI
  32. Hardin H, Helein H, Meyer K, Robertson S, Zhang R, Zhong W, et al. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of lncRNAs. Lab Invest. 2018;98(9):1133–42. · DOI
  33. Alzahrani FA, El-Magd MA, Abdelfattah-Hassan A, Saleh AA, Saadeldin IM, El-Shetry ES, et al. Potential effect of Exosomes Derived from Cancer Stem cells and MSCs on progression of DEN-Induced HCC in rats. Stem Cells Int. 2018;2018:8058979. · DOI
  34. Wu Q, He Y, Liu X, Luo F, Jiang Y, Xiang M, et al. Cancer stem cell-like cells-derived exosomal lncRNA CDKN2B-AS1 promotes biological characteristics in thyroid cancer via miR-122-5p/P4HA1 axis. Regen Ther. 2023;22:19–29. · DOI
  35. Wang L, He J, Hu H, Tu L, Sun Z, Liu Y, et al. Lung CSC-derived exosomal mir-210-3p contributes to a pro-metastatic phenotype in lung cancer by targeting FGFRL1. J Cell Mol Med. 2020;24(11):6324–39. · DOI
  36. Wang L, Yang G, Zhao D, Wang J, Bai Y, Peng Q, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019;18(1):86. · DOI
  37. Liu D, Li X, Zeng B, Zhao Q, Chen H, Zhang Y, et al. Exosomal microRNA-4535 of Melanoma Stem cells promotes metastasis by inhibiting Autophagy Pathway. Stem Cell Rev Rep. 2023;19(1):155–69. · DOI
  38. Li X, Liu D, Chen H, Zeng B, Zhao Q, Zhang Y, et al. Melanoma stem cells promote metastasis via exosomal miR-1268a inactivation of autophagy. Biol Res. 2022;55(1):29. · DOI
  39. Zhu Y, Huang S, Chen S, Chen J, Wang Z, Wang Y, et al. SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer. Cell Death Dis. 2021;12(5):449. · DOI
  40. Patnam S, Majumder B, Joshi P, Singh AD, Nagalla B, Kumar D, et al. Differential expression of SRY-Related HMG-Box transcription factor 2, Oligodendrocyte Lineage Transcription Factor 2, and Zinc Finger E-Box binding Homeobox 1 in serum-derived extracellular vesicles: implications for Mithramycin Sensitivity and targeted therapy in high-Grade Glioma. ACS Pharmacol Transl Sci. 2024;7(1):137–49. · DOI
  41. Shi L, Li B, Zhang Y, Chen Y, Tan J, Chen Y, et al. Exosomal lncRNA Mir100hg derived from cancer stem cells enhance glycolysis and promote metastasis of lung adenocarcinoma through mircroRNA-15a-5p/31-5p. Cell Commun Signal. 2023;21(1):248. · DOI
  42. Ji W, Bai J, Ke Y. Exosomal ZFPM2-AS1 contributes to tumorigenesis, metastasis, stemness, macrophage polarization, and infiltration in hepatocellular carcinoma through PKM mediated glycolysis. Environ Toxicol. 2023;38(6):1332–46. · DOI
  43. Hwang WL, Lan HY, Cheng WC, Huang SC, Yang MH. Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J Hematol Oncol. 2019;12(1):10. · DOI
  44. Gonzalez-Callejo P, Guo Z, Ziglari T, Claudio NM, Nguyen KH, Oshimori N, et al. Cancer stem cell-derived extracellular vesicles preferentially target MHC-II-macrophages and PD1 + T cells in the tumor microenvironment. PLoS ONE. 2023;18(2):e0279400. · DOI
  45. Ning J, Hou X, Hao J, Zhang W, Shi Y, Huang Y, et al. METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer. Cell Death Differ. 2023;30(10):2265–79. · DOI
  46. Huang S, Zhang P, Yin N, Xu Z, Liu X, Wu A, et al. Glioblastoma stem cell-derived exosomal miR-374b-3p promotes tumor angiogenesis and progression through inducing M2 macrophages polarization. iScience. 2024;27(3):109270. · DOI
  47. Bied M, Ho WW, Ginhoux F, Blériot C. Roles of macrophages in tumor development: a spatiotemporal perspective. Cell Mol Immunol. 2023;20(9):983–92. · DOI
  48. Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207. · DOI
  49. Yuan P, Xu X, Hu D, Chen Y, Fan J, Yao S, et al. Highly sensitive imaging of Tumor Metastasis based on the Targeting and polarization of M2-like macrophages. J Am Chem Soc. 2023;145(14):7941–51. · DOI
  50. Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomed Pharmacother. 2022;156:113906. · DOI
  51. Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, et al. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018;7(4):e1412909. · DOI
  52. Wu L, Ye S, Yao Y, Zhang C, Liu W. Oral Cancer stem cell-derived small extracellular vesicles promote M2 macrophage polarization and suppress CD4(+) T-Cell activity by transferring UCA1 and targeting LAMC2. Stem Cells Int. 2022;2022:5817684. · DOI
  53. Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated macrophages in Tumor Immunity. Front Immunol. 2020;11:583084. · DOI
  54. Yuan Y, Wang L, Ge D, Tan L, Cao B, Fan H, et al. Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells. Cancer Lett. 2021;500:98–106. · DOI
  55. Cheng WC, Liao TT, Lin CC, Yuan LE, Lan HY, Lin HH, et al. RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer. Int J Cancer. 2019;145(8):2209–24. · DOI
  56. Mirzaei R, Sarkar S, Dzikowski L, Rawji KS, Khan L, Faissner A, et al. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology. 2018;7(10):e1478647. · DOI
  57. Naseri M, Zöller M, Hadjati J, Ghods R, Ranaei Pirmardan E, Kiani J, et al. Dendritic cells loaded with exosomes derived from cancer stem cell-enriched spheroids as a potential immunotherapeutic option. J Cell Mol Med. 2021;25(7):3312–26. · DOI
  58. Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020;5(1):193. · DOI
  59. Yang Z, Zhao N, Cui J, Wu H, Xiong J, Peng T. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr). 2020;43(1):123–36. · DOI
  60. Santos JC, Lima NDS, Sarian LO, Matheu A, Ribeiro ML, Derchain SFM. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018;8(1):829. · DOI
  61. Yang J, Sun G, Hu Y, Yang J, Shi Y, Liu H, et al. Extracellular vesicle lncRNA Metastasis-Associated Lung Adenocarcinoma transcript 1 released from glioma stem cells modulates the inflammatory response of Microglia after Lipopolysaccharide Stimulation through regulating miR-129-5p/High mobility Group Box-1 protein Axis. Front Immunol. 2019;10:3161. · DOI
  62. Guo Z, Guo A, Zhou C. Breast Cancer stem cell-derived ANXA6-Containing exosomes sustain Paclitaxel Resistance and Cancer aggressiveness in breast Cancer. Front Cell Dev Biol. 2021;9:718721. · DOI
  63. Yao W, Guo P, Mu Q, Wang Y. Exosome-derived Circ-PVT1 contributes to Cisplatin Resistance by regulating Autophagy, Invasion, and apoptosis Via miR-30a-5p/YAP1 Axis in Gastric Cancer cells. Cancer Biother Radiopharm. 2021;36(4):347–59.
  64. Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X, et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36–46. · DOI
  65. Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95. · DOI
  66. Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107–22. · DOI
  67. Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, et al. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res. 2022;182:106311. · DOI
  68. Yang Q, Zhao S, Shi Z, Cao L, Liu J, Pan T, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40(1):120. · DOI
  69. Huang YH, Wang WL, Wang PH, Lee HT, Chang WW. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis. Int J Biol Sci. 2024;20(1):265–79. · DOI
  70. Chung WM, Molony RD, Lee YF. Non-stem bladder cancer cell-derived extracellular vesicles promote cancer stem cell survival in response to chemotherapy. Stem Cell Res Ther. 2021;12(1):533. · DOI
  71. Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186(8):1580–609. · DOI
  72. Luo H, Xia X, Huang LB, An H, Cao M, Kim GD, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619. · DOI
  73. Zhuang J, Shen L, Li M, Sun J, Hao J, Li J, et al. Cancer-Associated fibroblast-derived miR-146a-5p generates a Niche that promotes bladder Cancer Stemness and Chemoresistance. Cancer Res. 2023;83(10):1611–27. · DOI
  74. Liu L, Zhang Z, Zhou L, Hu L, Yin C, Qing D, et al. Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. Exp Cell Res. 2020;391(2):111956. · DOI
  75. Hasegawa T, Yashiro M, Nishii T, Matsuoka J, Fuyuhiro Y, Morisaki T, et al. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling. Int J Cancer. 2014;134(8):1785–95. · DOI
  76. Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932–48. · DOI · Paper page
  77. Owusu BY, Galemmo R, Janetka J, Klampfer L. Hepatocyte Growth Factor, a key tumor-promoting factor in the Tumor Microenvironment. Cancers (Basel). 2017;9(4). · DOI
  78. Heenatigala Palliyage G, Samart P, Bobbala S, Rojanasakul LW, Coyle J, Martin K, et al. Chemotherapy-induced PDL-1 expression in cancer-associated fibroblasts promotes chemoresistance in NSCLC. Lung Cancer. 2023;181:107258. · DOI
  79. Li Y, Wang R, Xiong S, Wang X, Zhao Z, Bai S, et al. Cancer-associated fibroblasts promote the stemness of CD24(+) liver cells via paracrine signaling. J Mol Med (Berl). 2019;97(2):243–55. · DOI
  80. Liu Y, Hua F, Zhan Y, Yang Y, Xie J, Cheng Y, et al. Carcinoma associated fibroblasts small extracellular vesicles with low miR-7641 promotes breast cancer stemness and glycolysis by HIF-1α. Cell Death Discov. 2021;7(1):176. · DOI
  81. Zhan Y, Du J, Min Z, Ma L, Zhang W, Zhu W, et al. Carcinoma-associated fibroblasts derived exosomes modulate breast cancer cell stemness through exonic circHIF1A by mir-580-5p in hypoxic stress. Cell Death Discov. 2021;7(1):141. · DOI
  82. Timaner M, Tsai KK, Shaked Y. The multifaceted role of mesenchymal stem cells in cancer. Semin Cancer Biol. 2020;60:225–37. · DOI
  83. Lyu T, Wang Y, Li D, Yang H, Qin B, Zhang W, et al. Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4. Exp Hematol Oncol. 2021;10(1):24. · DOI
  84. Hu Y, Liu H, Xiao X, Yu Q, Deng R, Hua L et al. Bone marrow mesenchymal stem cell-derived Exosomes Inhibit Triple-negative breast Cancer Cell Stemness and Metastasis via an ALKBH5-Dependent mechanism. Cancers (Basel). 2022;14(24). · DOI
  85. Gu H, Yan C, Wan H, Wu L, Liu J, Zhu Z, et al. Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis. Hum Cell. 2021;34(6):1812–29. · DOI
  86. Gao X, Zhou J, Wang J, Dong X, Chang Y, Jin Y. Mechanism of exosomal miR-155 derived from bone marrow mesenchymal stem cells on stemness maintenance and drug resistance in myeloma cells. J Orthop Surg Res. 2021;16(1):637. · DOI
  87. Li H, Li F. Exosomes from BM-MSCs increase the population of CSCs via transfer of miR-142-3p. Br J Cancer. 2018;119(6):744–55. · DOI
  88. Yao X, Mao Y, Wu D, Zhu Y, Lu J, Huang Y, et al. Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging mir-338-5p and targeting the Wif1/Wnt8/β-catenin axis. Cancer Lett. 2021;512:38–50. · DOI
  89. You B, Jin C, Zhang J, Xu M, Xu W, Sun Z, et al. MSC-Derived Extracellular vesicle-delivered L-PGDS inhibit gastric Cancer progression by suppressing Cancer Cell Stemness and STAT3 phosphorylation. Stem Cells Int. 2022;2022:9668239. · DOI
  90. Li W, Xin X, Li X, Geng J, Sun Y. Exosomes secreted by M2 macrophages promote cancer stemness of hepatocellular carcinoma via the miR-27a-3p/TXNIP pathways. Int Immunopharmacol. 2021;101(Pt A):107585. · DOI
  91. Chang J, Li H, Zhu Z, Mei P, Hu W, Xiong X, et al. microRNA-21-5p from M2 macrophage-derived extracellular vesicles promotes the differentiation and activity of pancreatic cancer stem cells by mediating KLF3. Cell Biol Toxicol. 2022;38(4):577–90. · DOI
  92. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. · DOI
  93. Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X, et al. Granulocytic myeloid-derived suppressor cells promote the stemness of Colorectal Cancer cells through Exosomal S100A9. Adv Sci (Weinh). 2019;6(18):1901278. · DOI · Paper page
  94. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast Cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res. 2016;76(11):3156–65. · DOI
  95. Babadag S, Altundag-Erdogan Ö, Akkaya-Ulum YZ, Çelebi-Saltik B. Evaluation of Tumorigenic properties of MDA-MB-231 Cancer stem cells cocultured with Telocytes and Telocyte-Derived Mitochondria following miR-146a inhibition. DNA Cell Biol. 2024. · DOI
  96. Rigg E, Wang J, Xue Z, Lunavat TR, Liu G, Hoang T, et al. Inhibition of extracellular vesicle-derived miR-146a-5p decreases progression of melanoma brain metastasis via notch pathway dysregulation in astrocytes. J Extracell Vesicles. 2023;12(10):e12363. · DOI
  97. Fabbri M. Natural killer cell-derived vesicular miRNAs: a New Anticancer Approach? Cancer Res. 2020;80(1):17–22. · DOI
  98. Lee J, Lee SA, Gu NY, Jeong SY, Byeon JS, Jeong DU, et al. Canine natural killer cell-derived exosomes exhibit Antitumor Activity in a mouse model of Canine Mammary Tumor. Biomed Res Int. 2021;2021:6690704. · DOI
  99. García-Ortega MB, Aparicio E, Griñán-Lisón C, Jiménez G, López-Ruiz E, Palacios JL et al. Interferon-Alpha decreases Cancer Stem Cell properties and modulates exosomes in Malignant Melanoma. Cancers (Basel). 2023;15(14). · DOI
  100. Chen J, Xu R, Xia J, Huang J, Su B, Wang S. Aspirin inhibits hypoxia-mediated lung cancer cell stemness and exosome function. Pathol Res Pract. 2019;215(6):152379. · DOI
  101. Chen JH, Wu ATH, Bamodu OA, Yadav VK, Chao TY, Tzeng YM et al. Ovatodiolide suppresses oral Cancer Malignancy by Down-regulating Exosomal Mir-21/STAT3/β-Catenin Cargo and Preventing Oncogenic Transformation of normal gingival fibroblasts. Cancers (Basel). 2019;12(1). · DOI
  102. Li H, Yang C, Shi Y, Zhao L. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma. J Nanobiotechnol. 2018;16(1):103. · DOI
  103. Yu L, Gui S, Liu Y, Qiu X, Zhang G, Zhang X, et al. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2. Aging. 2019;11(15):5300–18. · DOI
  104. Wu H, Mu X, Liu L, Wu H, Hu X, Chen L, et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020;11(9):801. · DOI
  105. Zhao X, Wu X, Qian M, Song Y, Wu D, Zhang W. Knockdown of TGF-β1 expression in human umbilical cord mesenchymal stem cells reverts their exosome-mediated EMT promoting effect on lung cancer cells. Cancer Lett. 2018;428:34–44. · DOI
  106. Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021;268:120546. · DOI · Paper page
  107. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93. · DOI · Paper page
  108. Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. · DOI · Paper page
  109. Ghorbaninezhad F, Alemohammad H, Najafzadeh B, Masoumi J, Shadbad MA, Shahpouri M, et al. Dendritic cell-derived exosomes: a new horizon in personalized cancer immunotherapy? Cancer Lett. 2023;562:216168. · DOI
  110. Li J, Li J, Peng Y, Du Y, Yang Z, Qi X. Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies. J Control Release. 2023;353:423–33. · DOI · Paper page
  111. Zhou Q, Wei S, Wang H, Li Y, Fan S, Cao Y, et al. T cell-derived exosomes in tumor immune modulation and immunotherapy. Front Immunol. 2023;14:1130033. · DOI
  112. Zhu T, Chen Z, Jiang G, Huang X. Sequential targeting hybrid nanovesicles composed of chimeric Antigen receptor T-Cell-derived exosomes and liposomes for enhanced Cancer Immunochemotherapy. ACS Nano. 2023;17(17):16770–86. · DOI
  113. Si C, Gao J, Ma X. Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications. Mol Cancer. 2024;23(1):134. · DOI
  114. Chen Y, Gong L, Cao Y, Liu Z, Wang Y, Cheng H, et al. Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer. J Control Release. 2024;366:395–409. · DOI
  115. Kim H, Park HJ, Chang HW, Back JH, Lee SJ, Park YE, et al. Exosome-guided direct reprogramming of tumor-associated macrophages from protumorigenic to antitumorigenic to fight cancer. Bioact Mater. 2023;25:527–40.
  116. Zhang J, Ji C, Zhang H, Shi H, Mao F, Qian H, et al. Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy. Sci Adv. 2022;8(2):eabj8207. · DOI
  117. Qiu H, Liang J, Yang G, Xie Z, Wang Z, Wang L, et al. Application of exosomes in tumor immunity: recent progresses. Front Cell Dev Biol. 2024;12:1372847. · DOI
  118. He C, Jaffar Ali D, Qi Y, Li Y, Sun B, Liu R, et al. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells. J Nanobiotechnol. 2023;21(1):154. · DOI
  119. Ishiguro K, Yan IK, Lewis-Tuffin L, Patel T. Targeting Liver Cancer Stem cells using Engineered Biological nanoparticles for the treatment of Hepatocellular Cancer. Hepatol Commun. 2020;4(2):298–313. · DOI
  120. Yong T, Zhang X, Bie N, Zhang H, Zhang X, Li F, et al. Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy. Nat Commun. 2019;10(1):3838. · DOI · Paper page
  121. Li L, Xiong Y, Wang N, Zhu M, Gu Y. Breast Cancer stem cells-derived Extracellular vesicles affect PPARG expression by delivering MicroRNA-197 in breast Cancer cells. Clin Breast Cancer. 2022;22(5):478–90. · DOI

Cited by

Sorted by citations

See all 64

Metadata

Authors
Li, Q., He, G., Yu, Y., Li, X., Peng, X., & Yang, L.
Venue
Stem Cell Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2024-11-22
Volume
15
Issue
1
ISSN
1757-6512
DOI
10.1186/s13287-024-04061-z
PMC
PMC11583673
Cited by
64
References
6
Language
en
Licence
Funders
  • National Natural Science Foundation of China (82372919, 82003040, 82303373)
  • China Postdoctoral Science Foundation (2021M703602)
  • Natural Science Foundation of Liaoning Province (2022-BS-137)
  • Scientific Research Fund of Liaoning Provincial Education Department (LJKMZ20221210, LJ212410159099, LJ212410159084)
  • Shenyang Municipal Bureau of Science and Technology (22-321-31-02)
  • Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program (RC220032, RC230600)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review